Literature DB >> 8635031

Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0).

S P Leitner1, A S Swern, D Weinberger, L J Duncan, R V Hutter.   

Abstract

BACKGROUND: The frequency of small (< or = 1 cm) axillary lymph node negative invasive breast cancers (T1a,b N0 M0) is increasing because of wider implementation of breast cancer screening. Identification of prognostic factors for these patients has been based largely on retrospective pathology review. The authors analyzed histologic factors recorded in the original pathology reports to determine predictors of recurrence for patients with T1a,b N0 M0 breast cancer.
METHODS: Two hundred eighteen patients were studied. Potential prognostic factors including measured millimeter tumor size in three dimensions, histologic grade, nuclear grade, and presence or absence of lymphatic vessel invasion were documented prospectively in routine surgical pathology reports of a large community (nonuniversity based) hospital. Follow-up was performed annually by the tumor registry.
RESULTS: With a median follow-up of 6.9 years (range, 3-15.8 years), overall recurrence free survival was 93%. Poor nuclear grade (hazard ratio, 5.8; 95% confidence interval, 1.70-19.82; P = 0.004) and lymphatic vessel invasion (hazard ratio, 4.6; 95% confidence interval, 1.34-15.61; P = 0.01) were independent predictors of recurrence. Only 10% of patients had cancers with both poor nuclear grade and lymphatic vessel invasion and their 67% 7-year recurrence free survival (RFS) rate was significantly lower than the 92% RFS rate observed for patients with one of these two factors (P = 0.007) and the 99% RFS for patients with neither poor risk factor (P = 0.0001).
CONCLUSIONS: The combination of poor nuclear grade and lymphatic vessel invasion identifies a very small subset (10%) of patients with T1a,b N0 M0 breast cancer with a significant relapse risk that warrants consideration of adjuvant systemic therapy. However, the majority of patients with T1a,b N0 M0 breast cancer have an exceptionally good prognosis.

Entities:  

Mesh:

Year:  1995        PMID: 8635031     DOI: 10.1002/1097-0142(19951201)76:11<2266::aid-cncr2820761114>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?

Authors:  Fuh Yong Wong; Connie Siew Poh Yip; Eu Tiong Chua
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

Review 2.  Adjuvant chemotherapy for tumors of one centimeter or less: the law of diminishing returns.

Authors:  S E Soule; K D Miller
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

3.  Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.

Authors:  G Houvenaeghel; A Goncalves; J M Classe; J R Garbay; S Giard; H Charytensky; M Cohen; C Belichard; C Faure; S Uzan; D Hudry; P Azuar; R Villet; P Gimbergues; C Tunon de Lara; M Martino; E Lambaudie; C Coutant; F Dravet; M P Chauvet; E Chéreau Ewald; F Penault-Llorca; B Esterni
Journal:  Ann Oncol       Date:  2014-01-07       Impact factor: 32.976

4.  Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients.

Authors:  Elizabeth A Mittendorf; Aysegul A Sahin; Susan L Tucker; Funda Meric-Bernstam; Min Yi; Khazi M Nayeemuddin; Gildy V Babiera; Merrick I Ross; Barry W Feig; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2008-09-25       Impact factor: 5.344

Review 5.  Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm.

Authors:  Christy A Russell
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

6.  In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases.

Authors:  Hua Yang; Guofu Fang; Xinping Huang; Jie Yu; Chia-Ling Hsieh; Hans E Grossniklaus
Journal:  Melanoma Res       Date:  2008-04       Impact factor: 3.599

7.  Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.

Authors:  Mary C Schroeder; Charles F Lynch; Taher Abu-Hejleh; Elizabeth A Chrischilles; Alexandra Thomas
Journal:  Clin Breast Cancer       Date:  2014-08-18       Impact factor: 3.225

8.  Investigation of SRP9 protein expression in breast cancer.

Authors:  Gizem Erdoğan; Didem Can Trabulus; Canan Kelten Talu; Mehmet Güven
Journal:  Mol Biol Rep       Date:  2021-11-02       Impact factor: 2.316

9.  Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.

Authors:  Stefania Gori; Matteo Clavarezza; Salvatore Siena; Jennifer Foglietta; Emiliana Tarenzi; Monica Giordano; Annamaria Molino; Claudio Graiff; Vittorio Fusco; Oscar Alabiso; Editta Baldini; Teresa Gamucci; Giuseppe Altavilla; Davide Dondi; Marco Venturini
Journal:  BMC Cancer       Date:  2012-04-30       Impact factor: 4.430

10.  Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?

Authors:  Mathew Purdom; Michael L Cibull; Terry D Stratton; Luis M Samayoa; Edward H Romond; Patrick C McGrath; Rouzan G Karabakhtsian
Journal:  Patholog Res Int       Date:  2010-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.